📰 Michael Strapazon News
Page 4 - Michael Strapazon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Strapazon. Real-time updates on events, politics, business and more.
February 26, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
February 26, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
February 15, 2022
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...
February 14, 2022
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...
February 8, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial...
February 8, 2022
/PRNewswire/ -- In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition...
February 8, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial...
February 8, 2022
THOUSAND OAKS, Calif., Feb. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the...
February 3, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a virtual Business Review Meeting at 8:00 a.m. ET on Tuesday, Feb. 8, 2022. Robert A. Bradway, chairman and chief...
January 20, 2022
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive,...